Revolution Medicines: Elironrasib shows’ compelling’ antitumor activity in trial

Revolution Medicines (RVMD) announced updated clinical data for elironrasib, a RAS(ON) G12C-selective inhibitor, in previously treated patients with KRAS G12C non-small cell lung cancer who had received a prior KRAS(OFF) G12C inhibitor. These results will be highlighted in an oral presentation at the AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics in Boston, October 23-25. “The compelling clinical activity, durable response and acceptable tolerability profile seen with elironrasib underscore the potential of this differentiated RAS(ON) G12C-selective inhibitor, including in patients who have progressed on G12C(OFF) inhibitors,” said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. “These findings reinforce the promise of our RAS(ON) inhibitor platform to deliver a range of therapies that target the active, GTP-bound state of RAS proteins with the potential to create new global standards of care.” As of the August 4, 2025 data cutoff date, patients with KRAS G12C NSCLC, who had received prior therapy with a KRAS(OFF) G12C inhibitor, were treated with elironrasib at the recommended Phase 2 dose of 200 mg orally twice daily and were evaluated on key safety and antitumor activity endpoints. These patients were heavily pretreated, with a median of three prior lines of therapy, with 92% having progressed on a prior KRAS(OFF) G12C inhibitor. Elironrasib demonstrated “compelling” antitumor activity, with a confirmed objective response rate of 42% and a disease control rate of 79%. The median duration of response was 11.2 months, and the median progression-free survival was 6.2 months. The median overall survival was not yet reached and 12-month OS rate was 62%. These results are from RMC-6291-001, an ongoing multicenter, Phase 1 trial designed to evaluate elironrasib monotherapy in patients with advanced KRAS G12C solid tumors.